A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Methylphenobarbital
Melengestrol
The risk or severity of adverse effects can be increased when Docetaxel is combined with Melengestrol.
Methylphenobarbital
Tepoxalin
The risk or severity of adverse effects can be increased when Docetaxel is combined with Tepoxalin.
Methylphenobarbital
Fluprednisolone
The risk or severity of adverse effects can be increased when Docetaxel is combined with Fluprednisolone.
Methylphenobarbital
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Docetaxel is combined with Antilymphocyte immunoglobulin (horse).
Methylphenobarbital
Peginterferon beta-1a
The risk or severity of adverse effects can be increased when Docetaxel is combined with Peginterferon beta-1a.
Methylphenobarbital
Tixocortol
The risk or severity of adverse effects can be increased when Docetaxel is combined with Tixocortol.
Methylphenobarbital
Vilanterol
The risk or severity of adverse effects can be increased when Docetaxel is combined with Vilanterol.
Methylphenobarbital
Dinutuximab
The risk or severity of adverse effects can be increased when Docetaxel is combined with Dinutuximab.
Methylphenobarbital
Blinatumomab
The risk or severity of adverse effects can be increased when Docetaxel is combined with Blinatumomab.
Methylphenobarbital
Vedolizumab
The risk or severity of adverse effects can be increased when Docetaxel is combined with Vedolizumab.
Methylphenobarbital
Obinutuzumab
The risk or severity of adverse effects can be increased when Docetaxel is combined with Obinutuzumab.
Methylphenobarbital
Dimethyl fumarate
The risk or severity of adverse effects can be increased when Docetaxel is combined with Dimethyl fumarate.
Methylphenobarbital
Carfilzomib
The risk or severity of adverse effects can be increased when Docetaxel is combined with Carfilzomib.
Methylphenobarbital
Teriflunomide
The risk or severity of adverse effects can be increased when Docetaxel is combined with Teriflunomide.
Methylphenobarbital
Belimumab
The risk or severity of adverse effects can be increased when Docetaxel is combined with Belimumab.
Methylphenobarbital
Eribulin
The risk or severity of adverse effects can be increased when Docetaxel is combined with Eribulin.
Methylphenobarbital
Wortmannin
The risk or severity of adverse effects can be increased when Docetaxel is combined with Wortmannin.
Methylphenobarbital
Pralatrexate
The risk or severity of adverse effects can be increased when Docetaxel is combined with Pralatrexate.
Methylphenobarbital
Bendamustine
The risk or severity of adverse effects can be increased when Docetaxel is combined with Bendamustine.
Methylphenobarbital
Belatacept
The risk or severity of adverse effects can be increased when Docetaxel is combined with Belatacept.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3